Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Finasteride treatment and male breast cancer: a register-based cohort study in four Nordic countries

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Smoking is associated with increased risk of myeloproliferative neoplasms: A general population-based cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Community-based football in men with prostate cancer: 1-year follow-up on a pragmatic, multicentre randomised controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Palliative Prostate Artery Embolization for Prostate Cancer: A Case Series

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Predictive value of AZGP1 following radical prostatectomy for prostate cancer: a cohort study and meta-analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

A potential link has been suggested between dispensed finasteride and increased risk of male breast cancer (MBC). Due to the rare occurrence of MBC, it remains to be established if such a relationship exists. The purpose of this study was to combine nationwide registers in four countries to assess the potential association between dispensed finasteride and MBC. A cohort of all males with dispensed finasteride in Denmark, Finland, Norway, and Sweden (1,365,088 person years) was followed up for up to 15 years for breast cancer, and compared to a cohort of males unexposed to finasteride. Individual-level register data included country, dates of dispensed finasteride, MBC diagnosis, and death. Incidence rate ratios (IRRs) were estimated using a generalized linear model with a Poisson distribution. An increased risk of MBC was found among finasteride users (IRR = 1.44, 95% confidence interval [95% CI] = 1.11-1.88) compared to nonusers. The IRR increased to 1.60 (95% CI = 1.20-2.13) when users in Norway and Sweden with short follow-up time were excluded. The highest IRR was seen among men with medium duration of dispensed finasteride, medium accumulated consumption of finasteride, and among men with first dispensed finasteride prescription 1-3 years prior to diagnosis. The analyses suggested possible ascertainment bias and did not support a clear relationship between dispensed finasteride and MBC. In conclusion, a significant association between dispensed finasteride and MBC was identified. However, due to limited data for adjustment of potential confounding and surveillance bias in the present study, further research is needed to confirm these results.

OriginalsprogEngelsk
TidsskriftCancer Medicine
Vol/bind7
Udgave nummer1
Sider (fra-til)254-260
Antal sider7
ISSN2045-7634
DOI
StatusUdgivet - jan. 2018

ID: 52698614